A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2024-04-29
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20
mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic
Gastroesophageal Reflux Disease (GERD).